These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 8700557

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway.
    Nakamura T, Sanokawa R, Sasaki Y, Ayusawa D, Oishi M, Mori N.
    Oncogene; 1996 Sep 19; 13(6):1111-21. PubMed ID: 8808684
    [Abstract] [Full Text] [Related]

  • 3. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.
    Cancer Res; 2000 Jun 01; 60(11):3081-7. PubMed ID: 10850460
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.
    Boerner JL, Danielsen AJ, Lovejoy CA, Wang Z, Juneja SC, Faupel-Badger JM, Darce JR, Maihle NJ.
    Oncogene; 2003 Oct 02; 22(43):6679-89. PubMed ID: 14555981
    [Abstract] [Full Text] [Related]

  • 6. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA, Cox AD.
    Oncogene; 2000 Sep 28; 19(41):4685-94. PubMed ID: 11032018
    [Abstract] [Full Text] [Related]

  • 7. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
    Saucier C, Papavasiliou V, Palazzo A, Naujokas MA, Kremer R, Park M.
    Oncogene; 2002 Mar 14; 21(12):1800-11. PubMed ID: 11896612
    [Abstract] [Full Text] [Related]

  • 8. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
    Huang L, Watanabe M, Chikamori M, Kido Y, Yamamoto T, Shibuya M, Gotoh N, Tsuchida N.
    Oncogene; 2006 Oct 19; 25(49):6457-66. PubMed ID: 16702953
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
    Wu CJ, Chen Z, Ullrich A, Greene MI, O'Rourke DM.
    Oncogene; 2000 Aug 17; 19(35):3999-4010. PubMed ID: 10962556
    [Abstract] [Full Text] [Related]

  • 10. Activation of tyrosine kinases by alpha1A-adrenergic and growth factor receptors in transfected PC12 cells.
    Zhong H, Minneman KP.
    Biochem J; 1999 Dec 15; 344 Pt 3(Pt 3):889-94. PubMed ID: 10585878
    [Abstract] [Full Text] [Related]

  • 11. Stimulation of mitogenic pathways through kinase-impaired mutants of the epidermal growth factor receptor.
    Ewald JA, Coker KJ, Price JO, Staros JV, Guyer CA.
    Exp Cell Res; 2001 Aug 15; 268(2):262-73. PubMed ID: 11478852
    [Abstract] [Full Text] [Related]

  • 12. Activation of the EGF receptor by insertional mutations in its juxtamembrane regions.
    Sorokin A.
    Oncogene; 1995 Oct 19; 11(8):1531-40. PubMed ID: 7478577
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
    Tari AM, Hung MC, Li K, Lopez-Berestein G.
    Oncogene; 1999 Feb 11; 18(6):1325-32. PubMed ID: 10022814
    [Abstract] [Full Text] [Related]

  • 17. A new function for phospholipase C-gamma1: coupling to the adaptor protein GRB2.
    Pei Z, Maloney JA, Yang L, Williamson JR.
    Arch Biochem Biophys; 1997 Sep 01; 345(1):103-10. PubMed ID: 9281317
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor.
    Fournier E, Dubreuil P, Birnbaum D, Borg JP.
    Oncogene; 1995 Sep 07; 11(5):921-31. PubMed ID: 7675451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.